-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, AML, Biological, therapy sequence, Diseases, Combinations, Therapies, MPN, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , TKI
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Francesco Passamonti1*, Florian H. Heidel, MD2*, Rohan C. Parikh3*, Derek Tang4*, Betsy J. Lahue4*, Jose Alberto Nadal4*, Keith L. Davis3*, Mayank Ajmera3*, Arianna Kee4* and Pranav Abraham4*

1Department of Medicine and Surgery, University of Insubria, Varese, Italy
2Internal Medicine II, University Hospital Jena, Jena, Germany
3RTI Health Solutions, Research Triangle Park, NC
4Bristol Myers Squibb, Princeton, NJ

Jonathan Pan, MD1, Sushil Ghimire, MD1, Molly Halloran, MD1*, Alexander Xu, BA2, Tingting Zhan, PhD3*, Gina Keiffer, MD4, Lindsay Wilde, MD4, Neil Palmisiano, MD, MS4, Margaret Kasner, MD, MSc4 and Adam F. Binder, MD4

1Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
2Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA
3Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University Hospital, Philadelphia, PA
4Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

Chih-Chiang Hu*, Rakhee Subramanian, MBBS* and Andrew Grigg, MBBS, MD, FRACP, FRCPA*

Olivia Newton-John Cancer Wellness and Research Centre, Austin Health and Department of Clinical Haematology, Austin Hospital, Heidelberg, VIC, Australia

Binav Baral, MD1*, Prasanth Lingamaneni2*, Trilok Shrivastava, MD3*, Maryam Zia4, Ishaan Vohra, MD2* and Krishna Rekha Moturi3*

1John H Stroger Hospital of Cook County, Chicago, IL
2John H. Stroger Hospital of Cook County, Chicago, IL
3John H Stroger Jr. Hospital of Cook County, Chicago, IL
4Division of Hematology/Oncology, John H Stroger Jr. Hospital of Cook County, Chicago, IL

Shelby Corman, PharmD, MS, BCPS1*, Namita Joshi, PhD, MS, BPharm1*, Tim Wert2*, Hrishikesh P Kale, PhD, MS, BPharm1*, Kala Hill2* and Amer M. Zeidan, MBBS, MHS3

1Pharmerit International, Bethesda, MD
2Taiho Oncology, Princeton, NJ
3Yale University School of Medicine and Yale Cancer Center, New Haven, CT

Gail J. Roboz, MD1, Christopher R. Cogle2, Daniel A. Pollyea, MD3, Mehrdad Abedi, MD4, Michael A. Thompson, MD, PhD5, Melissa Nifenecker6*, E. Dawn Flick6*, Pavel Kiselev6*, Chrystal U. Louis6*, Michelle Little, PhD6*, Irene DeGutis, PharmD7* and Harry P. Erba8

1Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
2University of Florida, Gainesville, FL
3University of Colorado, Aurora, CO
4University of California Davis, Sacramento, CA
5Advocate Aurora Health, Milwaukee, WI
6Bristol Myers Squibb, Princeton, NJ
7Bristol-Myers Squibb Company, Princeton, NJ
8Duke University, Durham, NC

Christina Poh, MD1, Ebaa Alobeidi, MD2*, Joseph Tuscano, MD1*, Aaron S Rosenberg, MD1, Rasmus T Hoeg, MD1* and Brian A Jonas, MD, PhD, FACP1

1Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, Sacramento, CA
2Department of Internal Medicine, University of California, Davis, Sacramento, CA

Vanessa E Kennedy, MD1, Theresa Keegan, PhD, MS2, Qian Li, MS3*, Fran Maguire, PhD, MPH4* and Lori Muffly, MD, MS5

1University of California- San Francisco, San Francisco, CA
2University of California, Davis, Sacramento, CA
3Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA
4California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Health, Institute for Population Health Improvement, Davis, CA
5Assistant Professor of Medicine, Stanford University School of Medicine, Stanford, CA

Joseph Mock, MD1, Cecilia Nguyen, M.D.2*, Puja C. Arora, MD3, Courtney Heron, B.S.4*, Karen K. Ballen, MD5, Lih-Wen Mau, PhD, MPH6*, Christa Lea Meyer, MS6*, Rajesh Balkrishnan, PhD7* and Steven M Devine, MD8

1Department of Medicine/Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
2Department of Medicine, University of Virginia, Charlottesvillee, VA
3Seidman Cancer Center, University Hospitals, Westlake, OH
4University of Virginia School of Medicine, Charlottesville, VA
5Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
6Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be the Match, Minneapolis, MN
7Cancer Population Health Core, UVA Cancer Center, University of Virginia School of Medicine, Charlottesville, VA
8National Marrow Donor Program (NMDP)/Be The Match, Minneapolis, MN

Mir Sohail Fazeli, MD, PhD1*, Divya Pushkarna1*, Ana Howarth1*, Margaret Hux1*, Mir-Masoud Pourrahmat1* and Clara Chen2*

1Evidinno Outcomes Research Inc., Vancouver, BC, Canada
2Bristol Myers Squibb, Princeton, NJ

*signifies non-member of ASH